159 related articles for article (PubMed ID: 10773414)
21. A 26-week carcinogenicity study of 2-amino-3-methylimidazo[4,5-f]quinoline in rasH2 mice.
Okamura M; Moto M; Muguruma M; Ito T; Jin M; Kashida Y; Mitsumori K
Toxicol Pathol; 2006; 34(2):199-205. PubMed ID: 16537296
[TBL] [Abstract][Full Text] [Related]
22. The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens.
Umemura T; Kodama Y; Hioki K; Nomura T; Nishikawa A; Hirose M; Kurokawa Y
Jpn J Cancer Res; 2002 Aug; 93(8):861-6. PubMed ID: 12716462
[TBL] [Abstract][Full Text] [Related]
23. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
24. Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene.
Mori I; Yasuhara K; Hayashi SM; Nonoyama T; Nomura T; Mitsumori K
Cancer Lett; 2000 May; 153(1-2):199-209. PubMed ID: 10779650
[TBL] [Abstract][Full Text] [Related]
25. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
[TBL] [Abstract][Full Text] [Related]
26. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
27. Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis.
Muto S; Katsuki M; Horie S
Cancer Sci; 2006 Sep; 97(9):842-7. PubMed ID: 16805855
[TBL] [Abstract][Full Text] [Related]
28. Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Rudmann D; Sargeant A; Morse M; Yonpiam R; Bonnette K; Albretsen J; Papagiannis C
Int J Toxicol; 2021; 40(3):207-210. PubMed ID: 33813924
[TBL] [Abstract][Full Text] [Related]
29. Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane.
Jin M; Matsumoto S; Dewa Y; Nishimura J; Saekusa Y; Hasumi K; Mitsumori K
Arch Toxicol; 2008 Oct; 82(10):771-7. PubMed ID: 18465119
[TBL] [Abstract][Full Text] [Related]
30. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Nomura T
Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
[TBL] [Abstract][Full Text] [Related]
31. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
32. Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice.
Storer RD; Cartwright ME; Cook WO; Soper KA; Nichols WW
Carcinogenesis; 1995 Feb; 16(2):285-93. PubMed ID: 7859360
[TBL] [Abstract][Full Text] [Related]
33. Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies.
Shah SA; Paranjpe MG; Atkins PI; Zahalka EA
Int J Toxicol; 2012; 31(5):423-9. PubMed ID: 22988008
[TBL] [Abstract][Full Text] [Related]
34. Carcinogenic susceptibility of rasH2 mice to troglitazone.
Jin M; Takahashi M; Moto M; Muguruma M; Ito K; Watanabe K; Kenmochi Y; Kono T; Hasumi K; Mitsumori K
Arch Toxicol; 2007 Dec; 81(12):883-94. PubMed ID: 17569031
[TBL] [Abstract][Full Text] [Related]
35. Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates.
Ohnishi Y; Arai T; Koshirakawa M; Horii N; Nakajo S; Urano K; Usui T; Tamaoki N; Ueyama Y
Exp Anim; 2001 Jan; 50(1):33-9. PubMed ID: 11326421
[TBL] [Abstract][Full Text] [Related]
36. Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Belich J; Vidmar TJ; Elbekai RH; McKeon M; Brown C
Int J Toxicol; 2017; 36(4):287-292. PubMed ID: 28553733
[TBL] [Abstract][Full Text] [Related]
37. Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246-96-0) in F344/N rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2003 May; (508):1-280. PubMed ID: 12844193
[TBL] [Abstract][Full Text] [Related]
38. Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis.
Umemura T; Kodama Y; Hioki K; Inoue T; Nomura T; Kurokawa Y
J Cancer Res Clin Oncol; 2001 Oct; 127(10):583-90. PubMed ID: 11599794
[TBL] [Abstract][Full Text] [Related]
39. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
40. Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains.
Ozaki M; Ozaki K; Watanabe T; Uwagawa S; Okuno Y; Shirai T
Toxicol Pathol; 2005; 33(2):267-71. PubMed ID: 15902970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
